Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
Rothschedl E
Record ID 32018000203
English
Authors' recommendations:
Although rituximab maintenance therapy provides essential benefits for patients with MCL after ASCT, relevant issues, including schedules of rituximab administration, the applicability of study results in older patients or patients with worse performance status, types of previously administered chemotherapeutical regimens, the role of minimal residual disease and, not least the impact of rituximab maintenance therapy on QoL need to be clarified. Due to the small number of MCL-affected patients, gathering significant evidence might prove difficult. However, more data is warranted to confirm the results of the LyMa trial.
Details
Project Status:
Completed
URL for project:
https://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2018
URL for published report:
http://eprints.hta.lbg.ac.at/1155/1/DSD_HSO_Nr.79.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1155/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Hematopoietic Stem Cell Transplantation
- Humans
- Lymphoma, Mantle-Cell
- Rituximab
- Transplantation, Autologous
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.